ClinicalTrials.gg
Active, not recruitingNCT06439576Updated Nov 12, 2026

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

An observational study in Diabetic Macular Edema, Neovascular Age-related Macular Degeneration and Retinal Vein Occlusion, sponsored by Hoffmann-La Roche. Active, not recruiting at 41 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hoffmann-La Roche · Observational

How we know

Updated Nov 12, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Retinal Vein Occlusion with a site in China — 8 open to participants now, 12 under way, 1 of them phase 3. Retinal Vein Occlusion · China.

Planned enrollment
4th of 11
1,000 · median 1,000
Started
2024
with 1 other
Observational
11 of 37
2 open now
Primary completion
2026-10
later than 7 of 11 live
Registered
26th of 37
by date
Lead sponsor
3 of 37
Hoffmann-La Roche

Among the 37 studies in Retinal Vein Occlusion with a site in China, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2024, is one of 11 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 26th registered.

Retinal Vein Occlusion

291 studies on the registry are indexed under Retinal Vein Occlusion; 33 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

8 of the 37 studies in Retinal Vein Occlusion with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Retinal Vein Occlusion studies recruiting now, 14 (74%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Retinal Vein Occlusion with a site in China, or all of them as a file.
02

Study summary

The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China. It is a primary data collection, non-interventional, prospective and retrospective, multi-center study designed to collect real-world, long-term data to gain clinical evidence on faricimab, by observing cohorts of patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) who are receiving treatment with faricimab.

03

Conditions studied

  • Diabetic Macular Edema
  • Neovascular Age-related Macular Degeneration
  • Retinal Vein Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will recruit patients who are naïve to anti-VEGF therapy in the study eye and those who have previously been treated with anti-VEGF therapy in the study eye. Study participation of patients previously treated with other anti-VEGF agents will be capped at a maximum of 40% of each indication enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have signed the
  2. Female and male Chinese patients, who had been diagnosed with nAMD, DME, or RVO by CFP, OCT, FFA, ICGA, or OCTA
  3. ≥50 years old for patients with nAMD, ≥18 years old both for patients with DME and RVO, at the time of signing informed consent (or the first administration of faricimab, whichever occurs first)
  4. Patients for whom the decision to receive treatment with faricimab is made prior to and independent from study participation
  5. Patients have received at least one faricimab treatment (the first dose) in the study eye

Exclusion criteria

Exclusion Criteria:

  1. Patients not receiving treatment for nAMD/DME/RVO with faricimab according to the standard of care and in line with the current summary of product characteristics (SPC) / labeling in China
  2. Active ocular inflammation or suspected / active ocular infection in either eye
  3. Received any other anti-VEGF treatment after faricimab
  4. Received any treatment within 6 months (180 days) before the first faricimab treatment in the study eye
  5. Any participation in any other clinical trials currently
  6. Patients could not provide the clinical data (visual acuity and OCT images) within 2 weeks (14 days) before receiving the initial faricimab injection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Patients with nAMD

    Drug: Faricimab

  • Cohort 2: Patients with DME

    Drug: Faricimab

  • Cohort 3: Patients with RVO

    Drug: Faricimab

Interventions

  • The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.

    Also known as: VABYSMO®

06

What researchers measure

Primary outcomes

  1. Change in Visual Acuity from Baseline at Month 12

    Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Visual Acuity Over Time

    Time frame: Baseline, Months 3, 6, 9, 12, 18, and 24

  2. Change in Visual Acuity from Baseline Over Time

    Time frame: Baseline, Months 3, 6, 9, 18, and 24

  3. Central Subfield Thickness Over Time

    Time frame: Baseline, Months 3, 6, 9, 12, 18, and 24

  4. Change in Central Subfield Thickness from Baseline Over Time

    Time frame: Baseline, Months 3, 6, 9, 12, 18, and 24

  5. Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other)

    Time frame: From Baseline to Month 24

  6. Number of Treatments per Year

    Time frame: Months 12 and 24

  7. Percentage of Eyes with Treatment Switch by Reason for Switch Over Time

    Time frame: Months 3, 6, 9, 12, 18, and 24

  8. Percentage of Eyes with Treatment Regimen Switch (Fixed, Treat-and-Extend, As Needed, or Other) by Reason for Switch Over Time

    Time frame: Months 3, 6, 9, 12, 18, and 24

  9. Total Number of Visits per Year

    Time frame: Months 12 and 24

  10. Number of Visits With or Without Treatment per Year

    Time frame: Months 12 and 24

  11. Time Interval Between Treatments per Year

    Time frame: Months 12 and 24

  12. Percentage of Eyes Treated with Ocular Concomitant Medications or Therapy by Type and Frequency During the Study

    Time frame: From Baseline until end of study (up to 3.5 years)

  13. Number of Participants Lost to Follow-Up More Than 6 Months at Months 12, 18, and 24

    Time frame: Months 12, 18, and 24

  14. Percentage of Eyes According to the Last Treatment Interval at Months 3, 6, 12, 18, and 24

    Time frame: Months 3, 6, 12, 18, and 24

07

Study locations

41 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Oct 2026, 29 months.

Of 26 observational studies under Retinal Vein Occlusion, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 69. This study's 29 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 3, 2024
StartActual
May 9, 2024
Primary completionActual
Oct 31, 2026was Nov 2026
CompletionEst.
Nov 15, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 15, 2026→Oct 31, 2026 (actual)
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Primary completion Nov 15, 2026→Oct 31, 2026 (now actual)
  2. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06439576
Lead sponsor
Hoffmann-La Roche
Collaborators
Shanghai Roche Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Jun 3, 2024
Start date
May 9, 2024
Primary completion
Oct 31, 2026
Completion
Nov 15, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion